Logo

ASBP

Aspire Biopharma Holdings, Inc.

ASBP

Aspire Biopharma Holdings, Inc. • NASDAQ
$0.11 ▲ 1.63% (+0.00)
Market Cap $5.23 M
52w High $15.80
52w Low $0.09
Dividend Yield 0%
P/E -0.17
Volume 7.46M
Outstanding Shares 49.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.941K ▲ $1.146M ▲ $-1.85M ▲ -95.337K% ▼ $-0.037 ▲ $0 ▲
Q2-2025 $0 $799.89K ▼ $-1.981M ▲ 0% $-0.04 ▲ $-1.453M ▲
Q1-2025 $0 $15.556M ▲ $-15.941M ▼ 0% $-0.33 ▼ $-15.651M ▼
Q4-2024 $0 $2.518M ▲ $-11.966M ▼ 0% $-0.25 ▼ $-11.075M ▼
Q3-2024 $0 $242.616K $-243.629K 0% $-0.005 $-242.616K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.948M ▲ $2.403M ▲ $13.87M ▲ $-11.467M ▼
Q2-2025 $206.233K ▼ $989.422K ▼ $10.606M ▲ $-9.617M ▼
Q1-2025 $1.347M ▲ $1.966M ▲ $8.918M ▲ $-6.953M ▼
Q4-2024 $3.633K ▼ $147.989K ▼ $1.688M ▲ $-1.54M ▼
Q3-2024 $16.541K $184.041K $985.629K $-801.588K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.85M ▲ $-1.104M ▲ $0 $2.846M ▲ $1.742M ▲ $-1.104M ▲
Q2-2025 $-1.981M ▲ $-1.14M ▲ $0 $0 ▼ $-1.14M ▼ $-1.14M ▲
Q1-2025 $-15.941M ▼ $-1.752M ▼ $0 $3.094M ▲ $1.343M ▲ $-1.752M ▼
Q4-2024 $-8.931M ▼ $479.569K ▲ $0 ▼ $-492.477K ▼ $-12.908K ▼ $479.569K ▲
Q3-2024 $-243.629K $-533.798K $38.258K $492.477K $-3.063K $-533.798K

Five-Year Company Overview

Income Statement

Income Statement Aspire Biopharma is essentially a pre‑revenue company at this stage. The available figures show no meaningful sales yet and only a very small reported loss, which likely understates the true economic cost of running trials, overhead, and product development. In practical terms, the business model has not yet been proven through recurring revenue, and the income statement is still in the “investment phase,” with future profitability entirely dependent on successful product approvals and commercialization rather than current operations.

Balance Sheet

Balance Sheet The reported balance sheet data are effectively blank, which limits visibility into cash reserves, assets, and any obligations. In reality, early‑stage biotechs like Aspire typically rely heavily on cash raised from investors and hold few tangible assets beyond cash and intellectual property. The key balance‑sheet risk is dependence on ongoing external funding to support trials and development, with little in the way of established hard assets or retained earnings to fall back on if capital markets tighten or timelines slip.

Cash Flow

Cash Flow The reported cash‑flow figures are minimal and not very informative, but the business should be assumed to be cash‑consuming rather than cash‑generating. Cash is likely being spent on clinical studies, regulatory work, intellectual‑property protection, and basic corporate costs, while incoming cash from product sales appears negligible so far. The central cash‑flow question is how long existing resources can support the development pipeline and whether the company can continuously secure new funding before any meaningful revenue arrives.

Competitive Edge

Competitive Edge Competitively, Aspire is trying to build a niche around a patent‑pending sublingual delivery platform that reformulates known drugs for faster action and potentially fewer side effects. This strategy can shorten development timelines versus completely new drugs and focuses on large, established markets like heart attack treatment, erectile dysfunction, and weight management. The moat rests on intellectual property, clinical proof that its sublingual forms are clearly better, and the ability to convince prescribers and patients to switch from familiar pills or injections. However, the company operates in a crowded healthcare space where large pharmaceutical and specialty drug‑delivery firms also pursue improved formulations, so Aspire’s long‑term competitive strength is not yet proven.

Innovation and R&D

Innovation and R&D Innovation is the main asset here. Aspire’s platform centers on turning existing drugs into fast‑acting powders absorbed under the tongue, with a lead program in sublingual aspirin for emergency heart situations, plus a consumer caffeine product as an early proof‑of‑concept. The pipeline extends the same idea to erectile dysfunction and a needle‑free version of semaglutide for diabetes and weight loss, both potentially attractive if technical and regulatory hurdles are cleared. The approach is scalable across multiple drug categories, but success depends on consistent clinical data, regulatory approvals, and the ability to execute several programs in parallel without overextending limited resources.

Summary

Aspire Biopharma is an early‑stage, SPAC‑listed biotech built around a single core idea: using a sublingual powder platform to make existing drugs faster‑acting and easier to tolerate. Financially, it is still in the pre‑revenue, capital‑dependent phase with limited disclosure on balance‑sheet strength and cash runway, and no demonstrated earnings power yet. Strategically, the company targets large, well‑known markets with reformulated products, which can reduce scientific risk but leaves it competing in spaces watched closely by much larger industry players. The overall picture is of a high‑uncertainty, innovation‑driven story where outcomes will be shaped by clinical trial results, regulatory decisions, partnership or licensing opportunities, and continued access to funding rather than by current financial performance.

NEWS

November 26, 2025 · 9:00 AM UTC

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Read more

November 6, 2025 · 9:00 AM UTC

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Read more

October 6, 2025 · 8:30 AM UTC

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Read more

October 3, 2025 · 11:30 AM UTC

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Read more

October 1, 2025 · 8:30 AM UTC

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Read more